scholarly journals In Vitro Antimicrobial Activity of a New Cephalosporin, Ceftaroline, and Determination of Quality Control Ranges for MIC Testing

2008 ◽  
Vol 53 (3) ◽  
pp. 1271-1274 ◽  
Author(s):  
Steven D. Brown ◽  
Maria M. Traczewski

ABSTRACT The spectrum of activity of ceftaroline was evaluated against 1,247 bacterial isolates representing 44 different species or phenotypic groups. For the majority of species, the activity of ceftaroline was comparable or superior to that of ceftriaxone. MIC and/or disk diffusion quality control ranges of ceftaroline were determined for five standard ATCC reference strains.

1987 ◽  
Vol 7 (1) ◽  
pp. 29-35 ◽  
Author(s):  
Peter C. Fuchs ◽  
Ronald N. Jones ◽  
Arthur L. Barry ◽  
Leona W. Ayers ◽  
Thomas L. Gavan ◽  
...  

2010 ◽  
Vol 64 (3) ◽  
Author(s):  
Biljana Dekić ◽  
Vidoslav Dekić ◽  
Niko Radulović ◽  
Rastko Vukićević ◽  
Radosav Palić

AbstractA series of new coumarin derivatives has been synthesized by condensation of 4-chloro-3-nitrocoumarin and the appropriate arylamine and sulfonamide in ethyl acetate in the presence of triethylamine. The synthesized compounds were screened for their in vitro antimicrobial activity against thirteen strains of bacteria and three fungal/yeast strains using disk diffusion assays. They were shown to possess a wide range of activities from almost completely inactive compounds to medium active ones. (4-[(5-Chloropyridin-2-yl)amino]-3-nitro-2H-chromen-2-one) showed similar activity against Klebsiella pneumoniae as tetracycline.


2017 ◽  
Vol 55 (10) ◽  
pp. 3130-3134 ◽  
Author(s):  
Stefan Riedel ◽  
Michael D. Huband ◽  
Helio S. Sader ◽  
Robert K. Flamm ◽  
Ronald N. Jones

ABSTRACTHigh-dose cefepime-tazobactam (1:1; WCK 4282), a novel antibacterial combination consisting of the β-lactamase inhibitor tazobactam and a fourth-generation cephalosporin, is under clinical development for the treatment of serious Gram-negative infections. A quality control (QC) study was performed to establish disk diffusion and MIC ranges for cefepime-tazobactam for multiple QC reference strains. The cefepime-tazobactam QC ranges for a fixed tazobactam MIC of 8 μg/ml and disk diffusion (30/20-μg disk) test methods were approved by the CLSI Subcommittee on Antimicrobial Susceptibility Testing in January 2015 and January 2016. These QC ranges will be important for accuratein vitroactivity evaluations of cefepime-tazobactam when tested against clinical Gram-negative bacteria during clinical studies and routine patient care.


Author(s):  
Joseph Olowo Arogbodo ◽  
Oyetayo Bolanle Faluyi ◽  
Festus Omotere Igbe

Purpose: The study aims to assess the antimicrobial activity of ethanolic leaf extracts of Hibiscus asper and Hibiscus sabdariffa against eight bacterial isolates. Materials and Methods:  An in vitro Antimicrobial activity of ethanolic leaf extract of the two plants against eight nosocomical and pathogenic bacteria viz; Pseudomonas aeruginosa (PAE), Proteus vulgaris (PVU), Klebsiella aerogenes (KAE), Staphylococcus aureus (SAU), Bacillus cereus (BCE), Escherichia coli (ECO), Moraxella catarrhalis (MCA) and Salmonella typhi (STY) was carried out using agar well diffusion assay with the concentration range of 3.13 – 100 mg/mL. Results: H. asper and H. sabdariffa showed significant difference (p< 0.05) in antimicrobial activity against BCE over the rest of the isolates. Inhibition zone diameters exhibited by the isolates to ethanolic leaf extract of H. asper was in descending order of BCE (15.00 ± 1.00a) >ECO (11.67 ± 0.58b) >SAU (7.67 ± 0.58c) >PAE (6.67 ± 0.58d) >STY (5.67 ± 0.58e) while that of H. sabdariffa was in the order BCE (15.33 ± 1.15a) > MCA (11.33 ± 1.15b) > SAU (11.00 ± 1.00bc) > KAE (9.67 ± 0.58c) > PAE (8.00 ± 1.00d) >PVU (7.67 ± 0.57e). PVU, KAE and MCA were resistant to the extract of H. asper while only STY was resistant to that of H. sabdariffa. Conclusion: H. sabdariffa extract demonstrated higher antimicrobial activity against the selected bacterial isolates than H. asper. However, the two extracts minimum inhibition concentrations (MICs) ranged from 25 mg/mL to 12.5 mg/mL. This is worthy of further exploration by pharmacological industries in the formulation of potent broad spectrum antibiotics for combating the present health challenge due to antimicrobial resistance.


Sign in / Sign up

Export Citation Format

Share Document